Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion type Assertion NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_head.
- NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion description "[Alemtuzumab is a chimeric CD52 monoclonal antibody with activity in CLL patients with fludarabine-refractory disease and 17p deletion.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_provenance.
- NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion evidence source_evidence_literature NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_provenance.
- NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion SIO_000772 21670470 NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_provenance.
- NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion wasDerivedFrom befree-2016 NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_provenance.
- NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_assertion wasGeneratedBy ECO_0000203 NP901719.RAb1zkukDwj6E8bXERmrsBtg-BKvXxOyLfDqVPXJSGcSI130_provenance.